SRT 3025
Alternative Names: SRT-3025Latest Information Update: 16 Jul 2016
At a glance
- Originator Sirtris
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action SIRT1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in United Kingdom (PO, Capsule)
- 23 Nov 2011 Sirtris completes enrolment in its phase I trial for Type 2 diabetes mellitus in USA (NCT01340911)
- 26 Jul 2011 Phase-I clinical trials in Type-2 diabetes mellitus in United Kingdom (PO)